Publications by authors named "E Bayam"
Article Synopsis
- Brain development involves the coordinated growth of structures necessary for forming neural circuits, with the corpus callosum being a crucial connection between brain hemispheres.
- Defects in the growth process, particularly in the development of callosal projection neurons, can lead to syndromic corpus callosum dysgenesis (CCD) and are associated with other conditions like microcephaly.
- The study identifies WDR47 as a key gene responsible for survival of callosal neurons and highlights its role in mitochondrial and microtubule maintenance, suggesting that mutations in this gene lead to a new neurodevelopmental syndrome involving corpus callosum abnormalities.
Prosthetic valve thrombosis (PVT) is a critical and life-threatening condition driven by multifactorial etiologies, including genetic predispositions. The study was designed as a single-center retrospective manner. Echocardiographic features and genetic test including factor II/prothrombin (G20210A), factor V Leiden (G1691A), factor V R2 (A4070G), apolipoprotein (Apo) B-100 (G10708A), ApoE (C112R), ApoE (R158C), methylenetetrahydrofolate reductase (MTHFR) C677T, MTHFR A1298C, factor XIII G103T (V34L), β-fibrinogen (455G>A), PAI-1 4G/5G, and HPA-1 GPIIIa (T196C) genotyping variations were assessed.
View Article and Find Full Text PDFArticle Synopsis
- Percutaneous closure of patent foramen ovale (PFO) helps prevent recurrent cerebral embolism, but device-related thrombosis can occur, leading to serious complications.
- A case is presented of a 40-year-old woman who developed a thrombus after PFO closure, which was successfully treated with a slow infusion of low-dose tissue plasminogen activator (t-PA).
- This case highlights that while acute thrombosis of PFO devices is rare, low-dose t-PA can be an effective treatment option if there are no contraindications.
Background: Optimal first-trimester anticoagulation is still challenging in pregnant women with mechanical heart valves (MHVs) requiring high-dose warfarin. This multicenter prospective study aims to determine the optimal anticoagulation regimens for pregnant patients with MHVs.
Methods: All women were allocated to one of three treatment options during first trimester including lone low-molecular-weight heparin (LMWH), combination of LMWH + 2.
Background: Prosthetic valve thrombosis (PVT) is a severe and life-threatening complication. Surgery and thrombolytic therapy (TT) carry a high risk, and in several circumstances, optimal anticoagulation with unfractionated heparin (UFH) infusion may be an alternative treatment. This study aimed to assess the results of UFH in patients diagnosed with both obstructive and non-obstructive PVT.
View Article and Find Full Text PDF